Literature DB >> 16785103

Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

B R Singh1.   

Abstract

Botulinum neurotoxins are multifaceted molecules, which are truly unique not only in their mode of action, but also their utility as a drug carrier either across the gut wall or to the nerve terminals. The molecule is divided in clear functional domains that can operate independently. This feature can be used to employ them as cargo carrier by linking other drugs or vaccines with the binding and translocation domains of BoNT. While the domain structures are largely independent of each other, the dynamic structure of these domains, especially that of the enzymatic domain (L chain), is quite different from the reported crystal structures for several BoNT serotypes and their enzymatic domain. This review discusses the comparative structures of BoNT in crystal and solution for their relevance to the molecular mechanism of BoNT action, especially in view of our recent discovery that the enzymatically active structure of the BoNT exists as a molten-globule and that of the endopeptidase domain as a novel PRIME conformation. Finally, a non-exhaustive discussion has been included to explain the long-lasting biological effects of certain serotypes of BoNT, based on the current knowledge of the structure-function of different serotypes of botulinum neurotoxins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785103     DOI: 10.1007/bf03033925

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  125 in total

Review 1.  Role of the molten globule state in protein folding.

Authors:  M Arai; K Kuwajima
Journal:  Adv Protein Chem       Date:  2000

2.  Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes.

Authors:  Y Fujinaga; K Inoue; T Nomura; J Sasaki; J C Marvaud; M R Popoff; S Kozaki; K Oguma
Journal:  FEBS Lett       Date:  2000-02-11       Impact factor: 4.124

3.  Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.

Authors:  M A Hanson; R C Stevens
Journal:  Nat Struct Biol       Date:  2000-08

4.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

5.  Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A.

Authors:  J A Chaddock; J R Purkiss; L M Friis; J D Broadbridge; M J Duggan; S J Fooks; C C Shone; C P Quinn; K A Foster
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

6.  Synaptobrevin/vesicle-associated membrane protein (VAMP) of Aplysia californica: structure and proteolysis by tetanus toxin and botulinal neurotoxins type D and F.

Authors:  S Yamasaki; Y Hu; T Binz; A Kalkuhl; H Kurazono; T Tamura; R Jahn; E Kandel; H Niemann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

7.  Tumour necrosis factor is in equilibrium with a trimeric molten globule at low pH.

Authors:  R Hlodan; R H Pain
Journal:  FEBS Lett       Date:  1994-05-02       Impact factor: 4.124

8.  Isolated light chain of tetanus toxin inhibits exocytosis: studies in digitonin-permeabilized cells.

Authors:  M A Bittner; W H Habig; R W Holz
Journal:  J Neurochem       Date:  1989-09       Impact factor: 5.372

9.  Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.

Authors:  John A Chaddock; John R Purkiss; Frances C G Alexander; Sarah Doward; Sarah J Fooks; Lorna M Friis; Yper H J Hall; Elizabeth R Kirby; Nicola Leeds; Hilary J Moulsdale; Anthony Dickenson; G Mark Green; Wahida Rahman; Rie Suzuki; Michael J Duggan; Conrad P Quinn; Clifford C Shone; Keith A Foster
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

10.  Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.

Authors:  G Schiavo; C C Shone; O Rossetto; F C Alexander; C Montecucco
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

View more
  17 in total

1.  The case of botulinum toxin in milk: experimental data.

Authors:  Oliver G Weingart; Tanja Schreiber; Conny Mascher; Diana Pauly; Martin B Dorner; Thomas F H Berger; Charlotte Egger; Frank Gessler; Martin J Loessner; Marc-Andre Avondet; Brigitte G Dorner
Journal:  Appl Environ Microbiol       Date:  2010-04-02       Impact factor: 4.792

Review 2.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

4.  Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E.

Authors:  Roshan V Kukreja; Shashi K Sharma; Bal Ram Singh
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

5.  Botulinum neurotoxin light chain refolds at endosomal pH for its translocation.

Authors:  Shuowei Cai; Roshan Kukreja; Sue Shoesmith; Tzuu-Wang Chang; Bal Ram Singh
Journal:  Protein J       Date:  2006-12       Impact factor: 2.371

Review 6.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

7.  The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.

Authors:  Shuowei Cai; Paul Lindo; Jong-Beak Park; Kruti Vasa; Bal Ram Singh
Journal:  Toxicon       Date:  2009-12-07       Impact factor: 3.033

8.  Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain.

Authors:  Anne-Marie Bryant; Jenny Davis; Shuowei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2013-02       Impact factor: 2.371

9.  Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex.

Authors:  Ellen R Goldman; George P Anderson; Jerry Conway; Laura J Sherwood; Melissa Fech; BaoHan Vo; Jinny L Liu; Andrew Hayhurst
Journal:  Anal Chem       Date:  2008-10-24       Impact factor: 6.986

10.  Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.

Authors:  Kruti B Patel; Shuowei Cai; Michael Adler; Brajendra K Singh; Virinder S Parmar; Bal Ram Singh
Journal:  Appl Environ Microbiol       Date:  2018-11-30       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.